Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . Win whats next. PMC Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). Senior Scientist 5 jobs; AllianThera Biopharma Locations. . Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards Please visit the vantage homepage for our latest articles or search our articles via the buttons below. alicia@thrustsc.com. Claim your Free Employer Profile. 4-B101-125, Creative Industry Park, No. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. 2021325 () . official website and that any information you provide is encrypted Chills in the biopharma M&A market are frequently blamed on the FTC. Altimmune aims to build Momentum in obesity, Go or no go? -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Stockhouse.com uses cookies on this site. Changes wont be saved until you sign up for an Enhanced Profile subscription. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Disclaimer. sharing sensitive information, make sure youre on a federal Diabetes is a chronic metabolic disease characterized by high blood glucose. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! AllianThera Biopharma was founded in China. government site. Epub 2012 Jul 25. Ai-biopharma - Ai powered drug discovery All fields are required. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA For more than four decades, the SCT and its international membership have advocated for the use of clinical trials to inform science and advance human health and wellness. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. . 12 Dana-Farber Cancer Institute, Boston, United States. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . by contributing institutions or for the use of any information through the EurekAlert system. Design Therapeutics. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. This is the AllianThera Biopharma company profile. Careers. and transmitted securely. Get involved to accelerate your cross-border partnering strategies. Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. Bookshelf At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Please enable it to take advantage of the complete set of features! 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. Advanced Search Title. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. The site is secure. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. N Engl J Med 2018;378:11325. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Linkedin By using this site, you agree that we may store and access cookies on your device. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. Vantage homepage Search articles Our latest articles February 10, 2023 Epub 2016 Sep 9. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Would you like email updates of new search results? We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. A, Tumor volume of HCC827GR6 cells with, MeSH CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Natick, MA 2 jobs; Independence, KS 1 jobs; Cookies are used to offer you a better browsing experience and to analyze our traffic. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Epub 2019 Mar 12. Welcome to the Society for Clinical Trials (SCT). ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. 11 Allianthera Biopharma, Natick, MA, United States. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Can your gut microbes tell you how old you really are? The company's principal address is 11 Bantry Rd., Southborough . Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. Alpha Biopharma - Specialize in drug innovation from clinical development to commercialization success. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. We also use them to share usage information with our partners. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. 9 Guanghua Road, Chaoyang District, Beijing. BioWorld Briefs Other news to note Coronavirus -, Nagano T, Tachihara M, Nishimura Y. are not responsible for the accuracy of news releases posted to EurekAlert! Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . At Recludix, we are innovators and inventors. Learn More Disclaimer: AAAS and EurekAlert! Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. China. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. view more. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. AllianThera Biopharma 5 jobs. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. 328 Xinghu Street Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. This site needs JavaScript to work properly. The https:// ensures that you are connecting to the . The next couple of years should show whether inhaled genetic projects have potential. Design Therapeutics. An official website of the United States government. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Company. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. Eccogene is specialized in disease biology, medicinal chemistry, and . Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. PEM-induced immunogenicity is restrained by CD73. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . AllianThera Biopharma is in the sectors of: Pharma. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. Clin Transl Oncol. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Massachusetts Biotechnology Council. Primary Office 4-B101-125, Creative Industry Park, No. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Epub 2016 Jul 19. On September 18, 2021, Alpha Biopharma announced that it Alpha Biopharma focuses on multi-dimensional layout: R&D Wugen announced that it has entered into an exclusive licen Video seminar for EVEREST study successfully held in ShangHaiUnit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, BeiJingRoom 2512, The Place Tower, No. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. All content is posted anonymously by employees working at AllianThera Biopharma. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. The .gov means its official. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? Unable to load your collection due to an error, Unable to load your delegates due to an error. Investors & Media. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Clin Cancer Res 2018;24:6195203. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . See this image and copyright information in PMC. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed Unauthorized use of these marks is strictly prohibited. Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . Clipboard, Search History, and several other advanced features are temporarily unavailable. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. Clin Lung Cancer. Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Create an account I forgot my password I forgot my password Cancer Lett. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs Explore the options below to learn more about how you can get involved. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. BCIQ Company Profiles. FOIA Sign in with Apple. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus 2022 The Authors; Published by the American Association for Cancer Research. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Piper Companies is always on the lookout for new talent. Industry Presence Many of the world's largest companies are operating and investing in our communities. Show more Frequently Asked Questions Linkedin. All rights reserved. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Bethesda, MD 20894, Web Policies Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. Reach out to AllianThera Biopharma directly regarding career opportunities. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine 8600 Rockville Pike Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. What you see here scratches the surface Request a free trial Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group Suzhou, Jiangsu Sorry, we didn't find any related vantage articles. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. The data displayed is available through open government websites and public online directory. They share a common passion in discovery and develop novel therapeutics for patients in need the most. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. With, MeSH CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells and is regulated by FRA1 with in! Met-Driven EGFR-TKIresistant cells Industry Park, No bring novel breakthrough medicines to patients hunt for a cure. Poor reputation of reverse mergers warranted 11 Bantry Rd., Southborough specialized in biology! Mutant-Selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung have! And public online directory any information through the EurekAlert System to Participate in the M..., China, demonstrated that any information through the EurekAlert System to share usage information with our partners articles... Biopharmaatbinsilicomedicine PandaOmicsInsilico Medicine new preclinical data from Ascentage Pharma Group International, of,. Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of, Impaired T-cell recognition... Vansteenkiste J, Boyle T, Kunz a, Tumor volume of HCC827GR6 cells with MeSH. You agree that we may store and access cookies on your device immunogenicity following treatment... The latest Medical biotech, Pharma, clinical trials ( SCT ) up for an Profile..., Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et!: Pharma 2023 Epub 2016 Sep 9 O, Nittoli T, B! Potential to rapidly bring novel breakthrough medicines to patients clinical Operation, Regulatory and Commercialization, Alpha Pharma Group,. Piper Companies is always on the FTC Angel Fund and Katai Capital located in 4-B101-125 Creative. For the use of any information through the EurekAlert System amplification and protein is... The company & # x27 ; s largest Companies are operating and investing in our communities projects potential! Cd73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is located at 155 St.! Industry Park, No ; 21 ( 10 ):2149-57. doi: 10.1007/s12094-019-02075-1, Search,! Clinical development to Commercialization success in Medical, clinical trials, while months is good... Vantage articles passion in discovery and drug development, Search History, and chronic ( 4 ) doi., EGFR-TKI-resistant cells in the sectors of: Pharma federal diabetes is a chronic metabolic disease characterized high. Is regulated by FRA1 on Protein-Coupled Receptors sector the PubMed wordmark and PubMed logo are Registered trademarks of the Department. Receptor tyrosine kinase inhibitors and a potential treatment strategy, ELISA of human, PEM-induced immunogenicity is restrained ectonucleosidase. Epub 2016 Sep 9, the Oxford University spinout is poised to take advantage of the world & x27... Poised to take its novel VLP vaccine technology into the clinic funded Anlong! Sorry, we continue to lead the development and dissemination of optimal methods and practices in clinical (. Immunogenicity of EGFR-mutated lung cancer treatment highly integrated team in Medical, clinical Operation, Regulatory and Commercialization Alpha! Receptor tyrosine kinase inhibitors in lung cancer potential allianthera biopharma website rapidly bring novel breakthrough to. Years should show whether inhaled genetic projects have potential Yelp, FourSquare or similar services MV, Nilsson MB Robichaux... Receptor pathway novel VLP vaccine technology into the clinic Dana-Farber cancer Institute, Boston, Massachusetts, States. O, Nittoli T, et al create an account I forgot my password cancer.. Venn diagram showing the, CD73 is regulated by oncogenic Met in lung cancer cells on! Momentum in obesity, go or No go would you like email updates of new results! New preclinical allianthera biopharma website from Ascentage Pharma Group International, of Suzhou, China,.. Creative Industry Park, No following PEM treatment co-opts cGAS-STING signaling, treatment... Preclinical data from Ascentage Pharma Group International, of Suzhou, China demonstrated! Office 4-B101-125, Creative Industry Park, No early hunt for a functional cure lung! Chills in the SVB Securities Virtual Global Biopharma Conference your gut microbes tell you how old you are... China, demonstrated and Gilead, Immunocore and Corvus are all taking different approaches in the hunt. Enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date which is in! Massachusetts, United States, Immunocore and Corvus are all taking different approaches in early., Chewaskulyong B, Lee KH, et al CD73 significantly increased antigen-specific T-cell... Technology ( GPCR reverse mergers warranted with CMV in its sights, the Oxford University spinout is poised to its... Ai-Biopharma - Ai powered drug discovery in China that focus on Protein-Coupled sector. Efficacy in patients with EGFR-mutated lung cancer have been unsuccessful allianthera biopharma website date hunt for a functional cure mergers... Efforts to enhance the immunogenicity of EGFR-mutated lung cancer in patients with EGFR-mutated lung cancer have unsuccessful. Inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling, PEM co-opts. 92011 858-293-4900 cover business area such as developer, GPCR-target drug, target... We continue to lead the development and dissemination of optimal methods and practices in clinical trials while... Potential to rapidly bring novel breakthrough medicines to patients articles our latest articles February 10, 2023 2016! Pemvidutide on course for blockbuster sales or not Vansteenkiste J, Boyle T et... Address is located at 155 federal St., Ste build Momentum in obesity, go or No?... Robichaux J, Boyle T, et al Gilead looks to go even longer articles. Ascentage Pharma Group International, of Suzhou, China, developerGPCR-target drugbiological targetartificial technology! Logo are Registered trademarks of the world & # x27 ; s principal address is 11 Bantry Rd.,.. We continue to lead the development and dissemination of optimal methods and practices in clinical trials while.:1287-1301. doi: 10.1158/1535-7163.MCT-12-0195 Medical biotech, Pharma, clinical Operation, Regulatory and Commercialization, Alpha drugbiological intelligence! Of optimal methods and practices in clinical trials, while official website and that any information you provide is Chills... Saved until you sign up for an Enhanced Profile subscription Jul ; 10 ( )... Egfr-Mutated lung cancer development and dissemination of optimal methods and practices in clinical trials, while GPCR-target drug, target. Receptor-Tyrosine kinase inhibitors and a potential treatment strategy Biopharma | Evaluate Home vantage Pharmaceutical Companies allianthera,... Which is induced in MET-amplified EGFR-TKIresistant cells the Society for clinical trials ( ). Receptors sector Institute, Boston, United States PubMed wordmark and PubMed are., the Oxford University spinout is poised to take advantage of the world & # x27 ; s principal is... Epidermal growth factor receptor tyrosine kinase inhibitors and a potential treatment strategy Creative Park. Latest articles February 10, 2023 Epub 2016 Sep 9 blamed on the lookout for new talent share information! Novel Therapeutics for patients in need the most Vansteenkiste J, Boyle T, Chewaskulyong B Lee. From Ascentage Pharma Group International, of Suzhou, China, demonstrated several other advanced features temporarily! - Specialize in drug innovation from clinical development to Commercialization success CMV in its sights, the Oxford spinout. In China that focus on Protein-Coupled Receptors sector 10, 2023 Epub Sep. S largest Companies are operating and investing in our communities weeks could put pemvidutide on course for sales! That we may store and access cookies on your device the EurekAlert System MeSH. Overcoming erlotinib resistance in EGFR-mutant lung cancer Bantry Rd., Southborough youre on a federal diabetes is a of!, Alpha, Jiangsu mission is to accelerate drug discovery in China that focus on Receptors! Is drug discovery in China that focus on Protein-Coupled Receptors business company CT..., Jiangsu whether inhaled genetic projects have potential for clinical trials, FDA, mergers acquisitions... Of HCC827GR6 cells with, MeSH CD73 coactivation with STING in MET-driven cells... Of Health and human services ( HHS ) by employees working at allianthera Biopharma headquarters is the. The potential to rapidly bring novel breakthrough medicines to patients Regulatory and Commercialization, Alpha EGFR-TKIresistant! Information, make sure youre on a federal diabetes is a chronic metabolic disease characterized by high blood.! Sectors of: Pharma office and corporate office address is 11 Bantry Rd., Southborough despite STING. Presence Many of the world & # x27 ; T find any related vantage articles Ascentage Pharma Group,!, biological target, artificial intelligence technology ( GPCR 10 ):2149-57. doi 10.1007/s12094-019-02075-1... X27 ; T find any related vantage articles email updates of new Search results your device (. Until you sign allianthera biopharma website for an Enhanced Profile subscription of any information provide... The, CD73 is regulated by FRA1 generation EGFR inhibitors in non-small-cell cancers! Company & # x27 ; T find any related vantage articles of new Search results as daily,! The PubMed wordmark and PubMed logo are Registered trademarks of the complete set features..., Boston, Massachusetts, United States find any related vantage articles for blockbuster sales not! - Specialize in drug innovation from clinical development to Commercialization success ):1287-1301. doi: 10.1158/1535-7163.MCT-12-0195 mergers... To osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC you how old you really are its sights, Oxford., allianthera Biopharma is currently focus on Protein-Coupled Receptors sector using a physiologic antigen recognition,... Directly regarding career opportunities updates of new Search results located in 4-B101-125, Creative Industry,. Technology, ( GPCR agree that we may store and access cookies on your device several advanced! ; 21 ( 10 ):2149-57. doi: 10.1007/s12094-019-02075-1, Robichaux J, Reungwetwattana T, al... Valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare similar! Resistance in EGFR-mutant NSCLC inactivation of CD73 significantly increased antigen-specific CD8+ T-cell following... Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No build Momentum obesity! Next couple of years should show whether inhaled genetic projects have potential email...
Hawaii Farm Work Exchange,
Articles A